Mandal Prakas Kumar, Baul Suvraneel, Dolai Tuphan Kanti, De Rajib, Chakrabarti Prantar
Department of Hematology, Nilratan Sircar Medical College, 8C/1/N, Roy Para Road, Kolkata, WB 700050 India.
Indian J Hematol Blood Transfus. 2017 Mar;33(1):144-147. doi: 10.1007/s12288-016-0706-7. Epub 2016 Jul 19.
Immune suppression is a crucial pillar for treatment of aplastic anemia. Cyclosporine monotherapy is an easily available, affordable therapeutic option with good safety profile.
This prospective study was conducted over a period of 2 years from June 2012 to July 2014. The diagnosis and response to treatment of aplastic anemia was established as per published criteria. Follow up was done at 3 and 6 months in order to assess the response.
57 patients of acquired aplastic anemia with median age of 37 years (6 to 81 years) were included in the study. 35 (62 %) cases were severe aplastic anemai, 16 (28 %) non severe aplastic anemia and 6 (10 %) were very severe aplastic anemia. At 3 months overall response rate (OR) was 7 (14 %) and at 6 months the OR rate of 11 (19.6 %) was achieved. Transiently raised creatinine, liver function abnormality and gum hypertrophy were the main side effects observed in this cohort.
Oral cyclosporine monotherapy at dose of 5 mg/kg/day is a relatively safe treatment option for resource poor patients with aplastic anemia.
免疫抑制是再生障碍性贫血治疗的关键支柱。环孢素单一疗法是一种容易获得、价格实惠且安全性良好的治疗选择。
这项前瞻性研究于2012年6月至2014年7月进行，为期2年。再生障碍性贫血的诊断和治疗反应依据已发表的标准确定。在3个月和6个月时进行随访以评估反应。
57例获得性再生障碍性贫血患者纳入研究，中位年龄37岁（6至81岁）。35例（62%）为重型再生障碍性贫血，16例（28%）为非重型再生障碍性贫血，6例（10%）为极重型再生障碍性贫血。3个月时总体缓解率（OR）为7例（14%），6个月时OR率达11例（19.6%）。该队列中观察到的主要副作用为肌酐短暂升高、肝功能异常和牙龈增生。
对于资源匮乏地区的再生障碍性贫血患者，每日5mg/kg剂量的口服环孢素单一疗法是一种相对安全的治疗选择。
